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Background
Fabry disease (FD) is a rare X-linked lipid storage
disorder, resulting from deficiency of the enzyme
alpha-galactosidase A (a-GAL). Consequent accu-
mulation of globotriaosylceramide (GB3) in most
cell types but particularly the vascular endothelium
cells, produces progressive damage to the kidneys,
skin, heart, and nervous system (1,2). Amyotrophic
lateral sclerosis (ALS) is a neurodegenerative dis-
order characterized by progressive loss of motor
neurons from the motor cortex, brainstem and
spinal cord (3).
Case history
We report a 38-year-old Caucasian male who
presented with a five-year history of weakness and
wasting in his right upper limb. He subsequently
developed weakness in all limbs and the bulbar
musculature. As a teenager, he experienced burning
sensations in the distal parts of his limbs, and had
significant diarrhoea. In his 20s he developed
angiokeratomata in the groin area. Combined with
cardiomyopathy and proteinuria, this led to a
diagnosis of FD at the age of 35 years.
Investigation revealed a c.299G4A mutation in
the a-GAL gene and an abnormally low leukocyte
activity of the a-GAL enzyme (1.96 pmol/punch/h).
T1, T2 and FLAIR (fluid attenuated inversion
recovery)-weighted MRI scans demonstrated wide-
spread white matter changes (Figure 1). He has
received Fabrizyme infusions every two weeks from
the age of 37 years.
At the time of the initial presentation to our
neuromuscular clinic, cognitive function and speech
appeared normal. There was no wasting or weakness
of the tongue, but occasional tongue fasciculations
were noted. There was fasciculation and global
muscle wasting of both upper limbs, more marked
on the right, and worst in the hands. There was
marked weakness of finger extension and of the
ulnar and median-innervated intrinsic hand muscles
bilaterally. The lower limb musculature was gener-
ally slim, but there was no observed focal wasting or
fasciculation. Lower limb tone was increased. There
was mild weakness of right hip flexion, but all other
lower limb muscle groups were of normal power.
The tendon reflexes were generally brisk and the left
plantar response was extensor.
Serial electrophysiological studies demonstrated
progressive changes with chronic and active denerv-
ation involving cervical, thoracic and lumbosacral
regions that fulfilled the El Escorial electrodiagnos-
tic criteria for ALS. Sensory nerve conduction was
normal despite the burning sensation our patient
had previously experienced; this is likely to be due to
the reduced sensitivity of electrophysiology in rec-
ording from small myelinated or unmyelinated
fibres. T1, T2 and FLAIR sequences demonstrated
widespread white matter changes (Figure 1). Spinal
MRI scans showed increased T2 signal in the left
side of the cord at the level of C4. Genetic testing
did not reveal a repeat expansion of C9orf72, a gene
associated with ALS particularly in the presence of
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extramotor symptomology (4). Subsequently, seven
years after he first noticed symptoms in the right
upper limb, he has developed symptomatic respira-
tory muscle and bulbar weakness requiring both
non-invasive ventilation and percutaneous
gastrostomy.
Discussion
FD is associated with neurological complications,
but the motor system is often spared (5). To our
knowledge, this is the first report of FD associated
with an ALS-like phenotype. FD has been con-
sidered primarily a vasculopathy (6), which would
not easily explain a motor neuron specific presen-
tation. However, defects in autophagy have been
observed in biosamples derived from patients with
FD and in a number of neurodegenerative condi-
tions including ALS. Study of renal tissue and
fibroblasts from FD patients demonstrated
increased staining of autophagy-associated markers
(microtubule-associated protein 1A/1B-light chain 3
(LC3) and p62/SQSTM1) (7). Defects in autop-
hagy have also been demonstrated in the brain of a
mouse model of FD: increased immunoreactivity for
LC3 and lysosomal-associated membrane protein 1
(LAMP-1) was accompanied by accumulation of
protein aggregates and neurodegeneration (8).
Several ALS-causing mutations have been identified
in the autophagy pathway including OPTN and
p62/SQSTM1, and impairment of autophagy has
been linked to the hallmark pathology of ALS, the
presence of cytoplasmic TDP-43 aggregates (9).
The G93A-SOD1 transgenic mouse model of ALS
shows histopathological similarities to the mouse
model of FD, with increased staining of autophagy-
associated markers (Figure 2) (10). We hypothesise
that in our patient, impaired autophagy as a result of
FD may have predisposed him to develop motor
neuron injury and the clinical phenotype of ALS.
There is some precedence in the association of
Parkinson’s disease with another lipid storage
disorder – Gauchers disease. If we are correct, it
remains to be determined why an autophagy defect
in FD leads specifically to ALS as opposed to
another neurodegenerative disease phenotype, but
this in itself might be an interesting source of
putative therapeutic targets.
Alternatively, the motor neuron disorder in this
patient may be the result of vascular insufficiency
secondary to FD. However, the clinical picture is
typical of ALS and the symmetry of the MRI white
matter changes is not consistent with the marked
asymmetry of the neuromuscular presentation.
This report highlights the findings in a single FD
patient and as such could be a chance finding.
However, given that both diseases are relatively
Figure 1. MRI brain scan from the patient with concurrent Fabry’s disease and amyotrophic lateral sclerosis. (A and B) T2 weighted
transverse MRI scan showing symmetrical white matter change; (C) Sagittal FLAIR MRI scan showing white matter changes in the
cerebral hemispheres; and (D) T2 weighted transverse MRI showing white matter changes in the brainstem.
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rare – the incidence of both is 1–2 per 100,000 in the
UK – a mechanistic link is worthy of consideration.
Moreover, as FD treatment continues to improve
life expectancy, it will be interesting to note whether
other similar patients are reported in the future.
This could have implications for the study and
treatment of both FD and ALS.
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Figure 2. Autophagy is dysregulated in mouse models of both Fabry’s disease and SOD1-G93A amyotrophic lateral sclerosis.
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